Brief: Opthea Completes Enrollment In First Pivotal Trial With Sozinibercept
14/02/2024 12:18
Feb 14 (Reuters) - Opthea Ltd OPT.AX :
* OPTHEA COMPLETES ENROLLMENT IN FIRST PIVOTAL TRIAL WITH
SOZINIBERCEPT
Source text for Eikon: ID:nGNX4V0B8D
Further company coverage: OPT.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ceryvyn Therapeutics
See all newsBrief: Ceryvyn Therapeutics Posts FY Profit Attributable A$330.4 Million
Brief: Opthea To Recommence Trading On ASX On Or Around June 3, 2026
Brief: Opthea Says Hamish George Assumes Role Of CFO
Brief: Opthea Logs FY Prelim Loss Attributable $162.8 Mln
Australia's Opthea cuts 80% staff, key executives to exit in deal to avert bankruptcy (updated)